daclatasvir/sofosbuvir / Generic mfg. - LARVOL DELTA

A CASE OF HEPATITIS C RELATED MIXED CRYOGLOBULINEMIA: A CASE REPORT (UEGW 2026) - "Imaging confirmed tense ascites, pleural effusion, and normal liver; echocardiography showed ischemic cardiomyopathy with pericardial effusion.Findings suggested mixed cryoglobulinemia secondary to chronic HCV with systemic involvement.The case posed a significant diagnostic and therapeutic challenge, given the coexistence of high viral load, Renal cell carcinoma which necessitated careful balancing between antiviral therapy, immunosuppression, and oncologic management.Following Multidiscplinary team (MDT) discussion with rheumatologist & nephrologist the patient was treated with sofosbuvir/daclatasvir and prednisolone (60 mg/day). Within two weeks, ascites and pleural effusion resolved completely, with improvement in proteinuria. After three months, virological response was achieved, and the patient was referred for surgical management.This case highlights an atypical presentation of HCV-related cryoglobulinemia with low SAAG ascites, emphasizing the importance of..."

Case report • Clinical • Cardiomyopathy • Cardiovascular • Complement-mediated Rare Disorders • Coronary Artery Disease • Diabetes • Genito-urinary Cancer • Heart Failure • Hematological Disorders • Hepatitis C • Hepatology • Hypertension • Infectious Disease • Inflammation • Ischemic stroke • Metabolic Disorders • Nephrology • Papillary Renal Cell Carcinoma • Pulmonary Disease • Renal Cell Carcinoma • Renal Disease • Respiratory Diseases • Solid Tumor • Type 2 Diabetes Mellitus

A novel way to increase the deceased donor pool by utilizing organs from hbv and hcv positive viremic donors- experience from a tertiary centre in India (TTS 2026) - " Donor HCV-RNA titres ranged from 12,85,466 to 2,82,50,000IU/mL.Both HBV donors were HBsAG positive and HBV-DNA negative.Both the liver recipients turned HCV+ve, with HCV-RNA titres ranging from 1883000 to 104400000IU/mL.They received Direct Acting Anti-viral (Sofosbuvir+daclatasvir),achieving EVR and SVR.None of the kidney recipients became seropositive for the entire duration of follow up... HCV+ve and HBV+ve viremic donors is an option to improve donor pool. Our study shows that despite universal transmission for liver recipients, short term graft function at 12 months is comparable to organs from non-viremic donors, with significant waiting time reduction. Extra-hepatic organs can be used safely, with negligible risk of transmission.Short term graft function is comparable to organs from non-viremic donors, with significant waiting time reduction."

Hepatitis B • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Liver Failure

Hepatitis C Virus Infection in the PERSIAN Guilan Cohort Study Population: Intrafamilial Transmission Incidence and Response to SOVODAK-Based Therapy. (PubMed, Health Sci Rep) - P4 | "Evidence of intrafamilial transmission was observed in this study, its frequency was extremely low and statistically negligible. Shared household items, although seemingly unlikely, such as toothpaste, may serve as a potential route of transmission within families, independent of direct interpersonal contact."

Journal • Fibrosis • Hepatitis C • Hepatocellular Cancer • Immunology • Infectious Disease • Inflammation • Oncology • Solid Tumor

Hepatocellular carcinoma is a viral reservoir during hepatitis C treatment with direct-acting antivirals (EASL 2026) - "Eight patients received sofosbuvir/ledipasvir ± ribavirin, six received sofosbuvir + daclatasvir ± ribavirin and one received sofosbuvir + ribavirin. During treatment of hepatitis C with DAA in cirrhotic patients with viable HCC, HCV persisted longer within HCC tissue than in non-tumoral liver tissue. These findings support the role of HCC as a viral reservoir during treatment of hepatitis C with DAA."

Fibrosis • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Liver Cirrhosis • Oncology • Solid Tumor

Atypical SDRIFE Associated with Hepatitis C Antiviral Treatment (EADV-Sp 2026) - "Materials and Methods A 38-year-old man with end-stage renal disease on dialysis and incidentally diagnosed hepatitis C developed a pruritic rash one week after starting sofosbuvir and daclatasvir...Conclusions SDRIFE should be suspected in any symmetric intertriginous eruption occurring after systemic drug exposure, even outside the typical beta-lactam class. This case highlights the need for vigilance regarding direct-acting antivirals for hepatitis C, particularly in vulnerable populations such as dialysis patients, and underscores the importance of reporting suspected reactions to pharmacovigilance to improve understanding of this under-recognized entity."

Dermatitis • Hematological Disorders • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Nephrology • Renal Disease

Machine learning-based prediction of treatment response in comorbid hepatitis C patients receiving DAA therapy: a real-world study from Pakistan. (PubMed, Front Public Health) - "This retrospective cohort study analyzed 221 comorbid HCV patients treated with Sofosbuvir + Daclatasvir ± Ribavirin combination therapy. ALT and AST consistently emerged as the strongest predictors associated with treatment failure. These findings support the potential of ML-based decision tools using routine clinical data in high-burden, resource-limited settings to guide risk stratification, optimize monitoring intensity, and inform public health strategies for HCV control and elimination in Pakistan and highlight the need for broader validation across larger, multicenter cohorts."

Journal • Real-world evidence • Retrospective data • Hepatitis C • Infectious Disease • Inflammation

The effect of HFE gene mutation and iron overload on sustained virological response in Egyptian chronic hepatitis C patients treated with daclatasvir and sofosbuvir. (PubMed, Korean J Intern Med) - "HFE mutations are associated with lower SVR rates and iron overload, but their impact appears mediated through disrupted iron metabolism. Iron overload emerged as the key independent predictor of treatment failure. These findings underscore the importance of evaluating iron status in conjunction with genetic factors to more accurately predict treatment outcomes in CHC patients receiving direct-acting antivirals."

Journal • Genetic Disorders • Hematological Disorders • Hepatitis C • Infectious Disease • Inflammation

Efficacy of Sofosbuvir and Daclatasvir Combination Treatment in Haemodialysis Patients with Chronic Hepatitis C. (PubMed, J Coll Physicians Surg Pak) - "Thus, combination of SOF/DCV is effective and safe for the treatment of HCV infection in haemodialysis patients. Key Words: Chronic hepatitis C virus, Daclatasvir, Haemodialysis, Sofosbuvir."

Journal • Hepatitis C • Infectious Disease • Inflammation

Virological and antifibrotic efficacy of antiviral treatment for hepatitis В+C in HIV-positive patients. (PubMed, Wiad Lek) - " In patients with HIV/HBV/HCV coinfection, interferon-free regimens that include two direct-acting antivirals, either alone or in combination with ribavirin, demonstrated 100 % virologic efficacy and the most beneficial effects on the liver reducing the degree of liver fibrosis."

Journal • Fibrosis • Hepatitis B • Hepatitis C • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis

HEPEDIAC: Study of DAA Treatment for Children and Adolescents With Active HCV Infection in Cambodia (clinicaltrials.gov) - P=N/A | N=21000 | Active, not recruiting | Sponsor: ANRS, Emerging Infectious Diseases | Recruiting ➔ Active, not recruiting

Enrollment closed • Hepatitis C • Infectious Disease • CD4

A cost-utility analysis of Glecaprevir/Pibrentasvir versus Sofosbuvir/Daclatasvir and Sofosbuvir/Velpatasvir for treatment of hepatitis C in Iran. (PubMed, Cost Eff Resour Alloc) - "The results showed that GLE/PIB is cost-effective compared with the two common medication regimens in Iran, SOF/DCV and SOF/VEL, consistent with Iran's national willingness-to-pay threshold based on one time the GDP per capita, making it a good treatment option for patients with hepatitis C."

HEOR • Journal • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Resistance-Driven Treatment Failure: A Challenge to HCV Elimination in Pakistan (ISPOR-EU 2025) - "Patients treated with sofosbuvir/velpatasvir had a lower Y93H RAS rate (52%) than those treated with sofosbuvir/daclatasvir (73%). Patients with cirrhosis and subtype 3b have a higher prevalence of NS5A RASs, which contribute to treatment failure. In real-world settings like Pakistan, the presence of these RASs poses challenges for retreatment, potentially leading to increased healthcare costs and delays in achieving national HCV elimination goals."

Fibrosis • Gastroenterology • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis

Stevens-Johnson syndrome associated with daclatasvir and sofosbuvir co-therapy in hepatitis C treatment: a rare case report. (PubMed, Ann Med Surg (Lond)) - "Even though SJS is rare, the possibility that it might have occurred due to sofosbuvir-daclatasvir highlights the need for clinicians to be vigilant while prescribing this regime and educate the patients about the signs and symptoms of SJS. Clinical practices can lower hazards and improve patient safety by implementing these measures."

Journal • Critical care • Hepatitis C • Herpes Simplex • Infectious Disease • Inflammation • Pneumonia • Steven-Johnson Syndrome

The Effectiveness of a Sofosbuvir/Daclatasvir Combination in the Treatment of HCV Infection in Patients from Mauritania Undergoing Chronic Hemodialysis. (PubMed, Medicina (Kaunas)) - "Adverse events included one case of acute pancreatitis, six cases of fatigue (17%), five cases of headache (15%), four cases of diarrhea (12%), three cases of nausea (9%), and four cases of insomnia (12%). The combination of sofosbuvir and daclatasvir is effective in patients with HCV undergoing chronic hemodialysis, achieving a 100% SVR rate."

Journal • CNS Disorders • Fatigue • Hepatitis C • Infectious Disease • Inflammation • Insomnia • Pain • Pancreatitis • Sleep Disorder

Safety and efficacy of different therapeutic regimens in Egyptian adults with moderate COVID-19 infection (EVEREST): a real-world retrospective study. (PubMed, Sci Rep) - "Patients were divided into four treatment arms: standard care, sofosbuvir/daclatasvir (sovodak) plus ivermectin, sofosbuvir/ledipasvir (SOF/LED) plus hydroxychloroquine, and SOF/LED plus ivermectin...Our study reveals that most tested antiviral combinations effectively reduced hospitalization days and progressive CT scans. These regimens demonstrated efficacy in treating moderate COVID-19 to prevent disease progression and complications."

Journal • Real-world evidence • Retrospective data • Infectious Disease • Novel Coronavirus Disease

Nationwide evaluation of hepatitis medication prescription patterns and costs in hepatitis B and C care. (PubMed, J Infect Public Health) - "While advancements have been made, gaps in diagnosis, access to care, and insurance coverage impede effective management. The findings emphasize the need for comprehensive public health strategies, including enhanced vaccination, better screening, and wider access to antiviral therapies. Policymakers must focus on improving healthcare infrastructure and public education to achieve the 2030 hepatitis elimination targets."

Journal • Hepatitis B • Hepatitis C • Infectious Disease • Inflammation

LIVERRISK SCORE EFFECTIVELY PREDICTS FIBROSIS PROGRESSION AND MORTALITY IN HCV PATIENTS TREATED WITH DIRECT-ACTING ANTIVIRALS (UEGW 2025) - "A total of 26(38.2%) patients underwent upper endoscopy, among whom 13(19.11%) had esophageal varices, 2(2.9%) had gastric or gastroesophageal varices (GOV), and 9(13.2%) presented with hypertensive gastropathy.46(75.4%) were treated with Sofosbuvir and Daclatasvir, followed by Sofosvubir and Velpatasvir for 9(14.8%). The LiverRisk score is an accurate tool to predict liver fibrosis and mortality in HCV patients treated with direct acting antivirals."

Clinical • Addiction (Opioid and Alcohol) • Cardiovascular • Cholestasis • Diabetes • Fibrosis • Gastroenterology • Hematological Disorders • Hepatitis B • Hepatitis C • Hepatology • Hypertension • Immunology • Inflammation • Liver Cirrhosis • Metabolic Disorders • Portal Hypertension • Thrombocytopenia

Complete response of HCV-associated primary extranodal Diffuse Large B-cell Lymphoma to direct-acting antiviral therapy alone assessed by [ 18 F]FDG PET/CT (EANM 2025) - "The patient received a 12-week course of DAA-based AVT with sofosbuvir and daclatasvir...Conclusion This report demonstrates that DAA-based AVT alone, as a first-line therapy, can induce a complete response in patients with HCV-associated DLBCL. Prospective studies are needed to further evaluate the outcomes of HCV-associated DLBCL treated with DAA-based AVT alone."

Clinical • FDG PET • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hepatitis C • Hepatology • Indolent Lymphoma • Infectious Disease • Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • BCL2 • BCL6 • CD20 • FCER2 • IRF4 • MME • PAX5

OUTCOMES OF DIRECT ACTING ANTIVIRAL AGENTS IN CHRONIC HEPATITIS C PATIENTS WITH PRE-EXISTING HEPATOCELLULAR CARCINOMA (AASLD 2025) - "Patients were administered various DAAs; daclatasvir+asunaprevir, sofosvubir+ribavirin, sofosbuvir+daclatasvir, ledipasvir/Sofosbuvir±ribavirin, ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin, glecaprevir/pibrentasvir, velpatasvir/Sofobuvir ± ribavirin. This study demonstrated that the DAAs achieved favorable treatment outcomes and was well tolerated in CHC patients with pre-existing HCC. HCC tumor stage, presence of viable HCC and ribavirin use was significantly associated with survival."

Clinical • Hepatitis C • Hepatocellular Cancer • Hepatology • Infectious Disease • Oncology • Solid Tumor

Longitudinal Changes in Immune Biomarkers Following Direct-Acting Antiviral Therapy in HIV/HCV-Coinfected Individuals in Indonesia. (PubMed, J Med Virol) - "A prospective study was conducted involving 132 HIV/HCV-coinfected individuals treated with sofosbuvir/daclatasvir for 12 or 24 weeks...DAA therapy was associated with significant reductions in sICAM-1 and sβ2M levels among HIV/HCV-coinfected individuals, irrespective of liver fibrosis stage. These findings highlight the immunomodulatory benefits of DAA therapy across different stages of liver disease in the Indonesian population."

Biomarker • Journal • Fibrosis • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • B2M • CD14 • ICAM1

High Efficiency and Safety of Hepatitis C Treatment Among People Who Inject Drugs in Vietnam. (PubMed, J Viral Hepat) - P4 | "PWID with detectable HCV RNA were referred to three public hospitals for a 12-week regimen of generic sofosbuvir/daclatasvir, with ribavirin if cirrhosis, and with CBO support for referral and adherence...Of the 1201 PWID screened with detectable HCV RNA, 1021 were enrolled: 96% male, median age 42 years, 45% HIV-infected, 16% with advanced liver fibrosis, 55% currently injecting, and 71.5% on methadone maintenance therapy (MMT)...High HCV cure rates can be achieved among PWID in LMICs such as Vietnam using a simple model of care, including a pangenotypic generic direct-acting antiviral combination and CBO support. Trial Registration: ClinicalTrials.gov identifier: NCT03537196."

Journal • CNS Disorders • Fibrosis • Hepatitis C • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • Psychiatry

Budget impact analysis of glecaprevir/pibrentasvir treatment for hepatitis C in Iran: a modelling study. (PubMed, BMJ Open) - "Considering the high price of the GLE/PIB compared with the available options in Iran, with the introduction of GLE/PIB into Iran's drug list, insurance coverage and appropriate allocation of necessary resources, a reduction in the cost burden because of hepatitis C treatment is expected for individuals and households. Additionally, with a well-regulated market share of existing medications, the optimal treatment choice for patients will be feasible."

HEOR • Journal • Hepatitis C • Infectious Disease • Inflammation

Efficacy of Sofosbuvir-Velpatasvir-Ribavirin Regimen for Retreatment of Chronic Hepatitis C in Patients With Prior DAA Failure: A Retrospective Study From a National Treatment Center. (PubMed, Int J Hepatol) - "In resource-limited settings where second-line DAAs (such as SOF/VEL/VOX) may be unavailable, optimizing first-line treatments is essential...Prior to retreatment, 27 patients had received a 12-week regimen of sofosbuvir and daclatasvir, while only three had been treated with the sofosbuvir-velpatasvir regimen... First-line DAAs are highly effective to treat naïve patients. In the absence of second-line options, retreatment with first-line DAAs (SOF/VEL plus ribavirin) is a viable alternative."

Journal • Retrospective data • Hepatitis C • Infectious Disease • Inflammation

PULMONARY SARCOIDOSIS – MORE THAN MEETS THE EYE (MTS 2025) - "Hepatitis C treatment initiated with Sofosbuvir and Daclatasvir...Mycophenolate Mofetil was started as steroid sparing agent but replaced with Methotrexate due to intolerance...Mosaic attenuation may indicate small airway granulomatous involvement. Therefore, histology and multidisciplinary discussion are very important."

Chronic Cough • Cough • Fibrosis • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Interstitial Lung Disease • Musculoskeletal Pain • Ocular Inflammation • Ophthalmology • Pneumonia • Pulmonary Disease • Respiratory Diseases • Sarcoidosis • Uveitis

An unusual survival for 6.5 years with end-stage hepatitis C related advanced liver cirrhosis following sustained virologic response with direct antiviral agents - A case report from A low-resource setting. (PubMed, Niger Med J) - "She received a six-month course of direct-acting antivirals (DAAs)daclatasvir and sofosbuvir and achieved sustained virologic response...This case underscores the transformative potential of DAAs in improving survival even among severely decompensated HCV-related cirrhotic patients. It highlights the need for expanded access and subsidization of DAAs in low-resource settings, where liver transplantation is not feasible, and emphasizes the role of aggressive, supportive management in bridging the treatment gap."

Journal • Cardiovascular • CNS Disorders • Epilepsy • Fibrosis • Gastroenterology • Hepatic Encephalopathy • Hepatitis C • Hepatocellular Cancer • Hepatology • Hypertension • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • Liver Failure • Nephrology • Oncology • Portal Hypertension • Renal Disease • Solid Tumor • Transplantation